Bio Essence Corp (BIOE)

Current Report Filed: 2026-04-24

Bio Essence acquired MediFlow AI (formerly AcuVital) software from Zhituo Software for $3.5 million in common stock, representing a significant asset addition to the company's product portfolio in healthcare AI technology.
The acquisition involves issuance of common stock valued at $3.5 million, which requires Board approval for final share count determination, creating potential dilution to existing shareholders depending on current stock valuation.
No prior material relationship existed between Bio Essence and Zhituo, suggesting this is a new strategic acquisition rather than an internal transaction, with the software's full technical specifications (source code, architecture, data, frameworks) transferred to the company.
The company is classified as an emerging growth company, indicating it is early-stage and may face higher execution risks in integrating and commercializing the acquired AI software asset.

Annual Report Filed: 2026-03-27

Bio Essence Corp is a smaller reporting company, which suggests it may have lower liquidity and less financial information available to investors.
The company is not required to file reports with the SEC, potentially limiting transparency for shareholders.
Bio Essence Corp had an aggregate market value of its common stock held by non-affiliates of $26.8 million as of December 31, 2025, indicating a relatively small market capitalization.

Important Information